TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04471155

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holep
Description: laser enucleation of the gland versus open enucleation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holep
Description: laser enucleation of the gland versus open enucleation
Study: NCT01551199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Channel Exposure Therapy- Veterans
Description: Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
Study: NCT05559957

Intervention type: BEHAVIORAL
Intervention: observation of delivery and neonatal outcomes
Description: MONITORING THE DELIVERY MODE EITHER CESAREAN OR VAGINAL, BESIDE THE NEONATAL OUTCOME AND MORBIDITIES IN BOTH GROUPS

Intervention type: BEHAVIORAL
Intervention: observation of delivery and neonatal outcomes
Description: MONITORING THE DELIVERY MODE EITHER CESAREAN OR VAGINAL, BESIDE THE NEONATAL OUTCOME AND MORBIDITIES IN BOTH GROUPS
Study: NCT01408355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273588
Description: Intravenous, 50 microgram, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273588
Description: Oral solution, 50 microgram, single dose
Study: NCT00755040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion
Description: Given as eye drops

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given as eye drops
Study: NCT02317393

Intervention type: OTHER
Group type: OTHER
Intervention: K5-RGD PET
Description: Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: FDG
Description: Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
Study: NCT00976352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV1-CMV-GAA (study agent) Administration
Description: rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV1-CMV-GAA (study agent) Administration
Description: rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMST
Description: After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMST
Description: After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
Study: NCT00977665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline mesylate
Description: rasagiline 1 mg tablet/day for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet for 48 weeks
Study: NCT01330433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoSeal Surgical Spray Group
Description: A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~* Patients weighing \< 3kg will receive 1ml of CoSeal~* Patients weighing 3-10kg will receive 1-2ml of CoSeal~* Patients weighing \>10kg will receive 2-4ml of CoSeal
Study: NCT02459730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART with GIC containing 1.25% CHX.
Description: Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ART with GIC.
Description: Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
Study: NCT02891057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-036)
Study: NCT00668902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]Pantoprazole
Description: \[13C\]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]Pantoprazole
Description: \[13C\]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]Pantoprazole
Description: \[13C\]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
Study: NCT01038388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/m² given IV or subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 100, 200, or 300 mg given PO
Study: NCT03682835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FDGard
Description: capsule containing peppermint oil and caraway oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule containing cellulose
Study: NCT02114151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
Study: NCT00742638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Investigational product: quetiapine fumarate tablet 25 mg and 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: Sodium valproate tablet 200 mg
Study: NCT04461327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Painful stimulations of major depressive patients
Description: All three pain mechanisms will be tested in one session lasting 1h approximately.~The mechanisms are tested in the following order:~1. Aδ and C threshold~2. Wind-up~3. CPM~(more details in detailed description)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: The blood test is made between 2 and 24 hours before the experimental procedure. The biological collection is made to measure medications' concentration if the patient takes antiepileptics and/or lithium, and to measure complete blood count (CBC).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: A clinical assessment will be made by a trained researcher.~(more details in detailed description)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social touch
Description: Stroking
Study: NCT01494584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezogabine/retigabine
Description: ezogabine dose escalation
Study: NCT01666808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Description: FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
Study: NCT03121001

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 3 Gy on day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Stem cell product infused according to BMT unit policy on day 0.
Study: NCT01666808

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
Study: NCT00944047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 MG/M2 IV over 30 minutes once a week for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 MG/M2 every two weeks for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth Factor Support
Description: * All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~* Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: * After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~* All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection.
Study: NCT02375295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
Description: Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
Description: Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
Study: NCT02624544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: esomex 40 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desonide
Description: topical corticosteroid desonid 0,1% b.i.d
Study: NCT03831321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: 50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Diagnostic cystoscopy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cystoscopy
Description: Diagnostic cystoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubricant Gel
Description: To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
Study: NCT03121001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: loading dose of 15 mg followed by 5 mg per day on day +5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 g every 8 h (until day 35) will be started on day 5
Study: NCT00955955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6(S)-5-MTHF(Deplin)
Description: Deplin is a medical food. Patients will take 15 mg/day of deplin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6(S)-5-MTHF(Deplin)
Description: Deplin is a medical food. Patients will take 15 mg/day of deplin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive substance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive substance
Study: NCT03831321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubricant Gel
Description: To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
Study: NCT04136886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Radiation: IMRT IMRT is to give 60Gy in 27 fraction

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Radiation: IMRT IMRT is to give 60Gy in 27 fraction
Study: NCT04612920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen, acetaminophen, oxycodone
Description: The timing of medications is the intervention.
Study: NCT02220894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Study: NCT03917368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scan of the internal jugular veins
Description: Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
Study: NCT00980070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric Restraint for Lumbar Puncture
Description: Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture Device
Description: Lumbar Puncture positioner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Lumbar Puncture positioner
Study: NCT02963974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: Implantation
Study: NCT03856710

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: self-gripping mesh
Description: The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled mesh
Description: The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
Study: NCT03868865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative mind-body-medicine group program
Description: The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
Study: NCT03769779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FloraGLO Lutein
Description: Lutein (FloraGLO™) in safflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: Safflower Oil
Study: NCT04141527

Intervention type: PROCEDURE
Intervention: Spinal analgesia
Description: Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in systolic pressure to \<100 mmHg or a decrease \>20% from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.

Intervention type: PROCEDURE
Intervention: Spinal analgesia
Description: Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in systolic pressure to \<100 mmHg or a decrease \>20% from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.
Study: NCT04425005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Home-based exercise training, supervised by videoconference.
Study: NCT02447822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: 6.0 mg/kg vs 4.5 mg/kg Thymoglobulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: 6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
Study: NCT03619590

Intervention type: OTHER
Intervention: Data Collection
Description: When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
Study: NCT00072761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfusion therapy
Description: Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
Study: NCT01619202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Anticipation -Perception Training
Description: Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
Study: NCT04211922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib Capsules
Description: Alkotinib 400mg QD
Study: NCT02080975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data Collection During Atrial Flutter Ablation
Description: All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
Study: NCT01774864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8159 (Udenafil)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8159 (Udenafil)
Study: NCT02517190

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: neuro-endocrine measurements
Description: psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids

Intervention type: OTHER
Group type: OTHER
Intervention: immunological measurements
Description: blood cell counts, B2 integrins, cytokines, C-reactive protein

Intervention type: OTHER
Group type: OTHER
Intervention: cellular energy metabolism measurements
Description: purines, lactate
Study: NCT04537676

Intervention type: OTHER
Intervention: No intervention, this is an observational study
Description: No intervention
Study: NCT01857193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib (LEE011)
Description: LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib (LEE011)
Description: LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
Study: NCT02406833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGF-β2 antisense oligonucleotide
Description: intravitreal injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Description: Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
Study: NCT01774864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00538590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen Matrix in Glaucoma Filtering Surgery
Description: Collagen Matrix implantation in Glaucoma Filtering Surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C(MMC) and glaucoma filtering surgery
Description: If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.